Table III.
NCI Grading* | |||||
---|---|---|---|---|---|
Time period of Ganciclovir given: | 0–I | II–III | IV | ||
Transplant to 12 weeks: | |||||
Neutropenia | 8/9 | 1/9 | 0 | ||
Anemia (Hemoglobin) | 4/9 | 5/9 | 0 | ||
Thrombocytopenia | 9/9 | 0 | 0 | ||
Creatinine | 3/9 | 6/9 | 0 | ||
12 weeks to IV Ganciclovir discontinued (patient specific): | |||||
Neutropenia | 8/9 | 1/9 | 0 | ||
Anemia (Hemoglobin) | 6/9 | 3/9 | 0 | ||
Thrombocytopenia | 9/9 | 0 | 0 | ||
Creatinine | 4/9 | 5/9 | 0 | ||
Time from IV Ganciclovir therapy discontinuation to study completion: | |||||
Neutropenia | 8/9 | 1/9 | 0 | ||
Anemia (Hemoglobin) | 7/9 | 2/9 | 0 | ||
Thrombocytopenia | 9/9 | 0 | 0 | ||
Creatinine | 2/9 | 6/9 | 1/9 | ||
*NCI Grading | |||||
Adverse Event | 0 | I | II | III | IV |
Neutropenia | WNL | ≥1500–<2000/mm3 | ≥1000–<1500/mm3 | ≥500–<1000/mm3 | <500/mm3 |
Anemia (Hb) | WNL | LLN- 10 g/dL | 8–10 g/dL | 6.5–8 g/dL | <6.5 g/dL |
Thrombocytopenia | WNL | <LLN -75,000/mm3 | ≥50,000–<75,000/mm3 | ≥10,000–<50,000/mm3 | <10,000mm3 |
Creatinine | WNL | >ULN-1.5 × ULN | ≥ 1.5–3 × ULN | ≥ 3–6 × ULN | ≥ 6 × ULN |